GENEVA, Illinois (9 November, 2021) – Roquette, a global leader in plant-based ingredients, pioneer of plant proteins and world-leading provider of pharmaceutical excipients, has today announced the launch of its ready-to-use, pharmaceutical grade solution for vegetarian softgel capsule formulation – LYCAGEL® PREMIX. Developed based on Roquette’s market-first pea starch technology – LYCAGEL® – launched in 2020, the new softgel blend provides manufacturers with an easy-to-use and convenient solution that ensures fast and reproducible scale-up for both nutraceutical and pharmaceutical applications.
A complete, plant-based powder, LYCAGEL® Premix enables capsule characteristics comparable to gelatin softgels, including excellent capsule strength, seal integrity, quick drying time with no stickiness, fast disintegration, and improved performance thanks to high thermal and chemical stability. Supporting non-GMO, halal, kosher and clean-label claims, LYCAGEL® PREMIX offers manufacturers an easy-to-use solution which eliminates dosing steps.
“Accessing the right quantities of raw materials is not always straightforward. LYCAGEL® PREMIX eliminates the need for manufacturers to manage multiple raw material inventory and simplifies processes, like handling and storage, as well as streamlining manufacturing through the simple addition of water and glycerol to the powder,” said Paul Smaltz, Vice President of Roquette Pharmaceutical Solutions.
Smaltz adds: “Available as a drop-in solution for customers’ existing systems, it is now easy for manufacturers to adopt the premix into current manufacturing set-ups without requiring re-tooling of the line. This eliminates the need for dosing of individual ingredients, while also minimizing the risk of variability and probability of production failure. We look forward to seeing what the future holds for LYCAGEL® PREMIX.”
LYCAGEL® PREMIX is available with immediate effect – for more information, please visit this page.
Media contacts
Corporate Communications
Carole Petitjean
[email protected]
Global Pharmaceutical Communications
Emily Delommez
[email protected]